The combination of oxaliplatin-based treatments ( oxaliplatin plus infusional 5-fluorouracil and leucovorin [ FOLFOX ] or oxaliplatin plus capecitabine [ CapeOX ] ) and bevacizumab is a standard chemotherapy regimen for metastatic CRC ( mCRC ) .